Hibiscus Petroleum Bhd – undervalued?
Since my last article on 2/9/18, the above were announced (especially the side-track) that were not accounted in the production estimates. The value of the company was not looked at in detail before.
Further study indicated that the Anasuria Cluster is naturally depleting at around 4% annually. So the GUA-P2 side-track (P2 ST) came at the right time. Two scenarios were taken, one with 1,000 bpd from P2 ST and the other, high case, 2,000 bpd from P2 ST. These production levels assumed an up-time of 88%.
Unfortunately or fortunately there isn’t sufficient data to estimate the depletion rate for North Sabah. The estimated production is revised down to 5,800 bpd from 6,100 bpd for financial year 2019 with an up-time of 96%.
Both production levels are shown in the next two graphs:
The financial figures are as shown below:
Take note the Anasuria-Vendor “tax” included where it become payable should oil price exceed US 75/b.
Source: Hibiscus: Page 4 of circular to shareholder dated 20/1/16
The reason tax was not included was the complexity of it. The focus of the valuation is on how good Management is in extracting oil at the lowest cost possible.
Also with current accounting rules, the frequent (re)valuation of assets (tangible & intangible) are creating a lot of impairment, write-back as well as negative goodwill. Other than negative goodwill, all impairment and write-back has been ignored in the assessment of book value shown below.
North Sabah was bought for US 25 million, the P2 reserve was given as 31 million barrels. That mean US$ 0.80 per barrel; if the reserve figure taken is correct (the RISC’s report is not available).
LEAP valued Anasuria Cluster at US$ 16.43 per barrel while the latest North Sabah (1/1/18) was valued at only US$ 6.38 per barrel. Therefore, there might be another revaluation during the financial year 2019 resulting in a potential Net Tangible Asset (NTA) of RM 1.41 per share.
There could be a perfectly rational reason why North Sabah should be valued lower than North Sea, thus, a lower US$ 12 per barrel and P2 reserve of 18.3 mb (20.45 less 1 year production) was assumed for the potential revaluation.
Today, paying RM 0.97 per share for potentially a RM 1.12 (diluted RM 1.18) NTA is a discount of 20% (diluted 18.5%). (19/9/18 - these discounts were corrected; the diluted NTA per share in the previous table did not take into consideration of the conversion "payment" of Warrant C to "mother" share of RM 1.06 / RM 1.12 in 2020 and 2021 respectively that will then increase the share capital.)
While retained profit appears high, a lot of it is from the negative goodwill and not distributable. Should the oil price fall below US$ 70 per barrel, there might be impairment and this will be backed out of the retained profit. Therefore, the EPS being estimated in the above table ignored this (negative goodwill).
Oil (& gas) exploration / production companies the world over had their reserve valued and parked under intangible asset. Hibiscus is no different.
And as oil (& gas) is produced, amortization is deducted; currently this is around US$ 41 per barrel (sold).
In some form of order (not strictly) of severity, the risks are;
The P2-ST will more than replace the natural depletion of the Anasuria Cluster production. A base case (1,000 bps) and a high case (2,000 bpd) production from P2-ST were considered.
North Sabah was reviewed and revised down to 5,800 bpd from 6,100 bpd.
These revisions would result in a potential 2.67 to 2.88 time increase in production compared with 2018 that will result in much improve cash flow that could cause (identified) projects to be brought forward to further improve production as well as productivity.
An Anasuria Vendor “tax” was included in the financial model to reflect the agreement entered into back in 2015.
With the LEAP Energy’s report on the Anasuria Cluster reserve valued at US$ 16.43 per barrel, the North Sabah reserve could be revalued this financial year 2019 resulting in a potential NTA of RM 1.41/share (RM 1.18 diluted).
IS HIBISCUS NOT UNDERVALUED?!?
Thank you for reading.
Disclosure: I and my family own shares in Hibiscus.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Buy / sell at your own risk.
Created by teoct | Jul 23, 2020